Interim analysis of a single-arm, phase II study of bevacizumab (BV) with modified OPTIMOX1 as first-line treatment of patients with metastatic colorectal cancer (mCRC): TCOG-GI0802. Outcomes of ...
Development of the patient-reported version of the common terminology criteria for adverse events (PRO-CTCAE). Background: This prospective study comprehensively examined quality of life (QOL) after ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
IT has been established that removal of all the pelvic viscera can be accomplished with a mortality of 25 per cent or less and that the resultant physiologic readjustments permit a comfortable and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results